INTRODUCTION
Renal anemia is an avoidable and critical complication in cases of
chronic renal failure. A recombinant human EPO (rHuEPO) has given a
privilege to chronic kidney disease (CKD) patients from blood
transfusions, but there are also some difficulties such as pain when
administering the drug injection and the complexity of handling the drug
for injection. In recent years, hypoxia-inducible factor prolyl
hydroxylase (HIF-PH) inhibitors, which are orally administrable drugs
for treating renal anemia, have been used [1]. The drug induces
erythropoietin production via HIF, reducing the difficulties in renal
amenia patients with rHuEPO injection. However, along with the many
benefits, cautions have also been pointed out when using HIF-PH
inhibitors. There are some concerns about its effects on cancer cells
and retinal hemorrhage 2-4. Roxadustat is an oral
HIF-PH inhibitor that stimulates erythropoiesis. Here, we showed a case
of central hypothyroidism caused by roxadustat with a summary of our
similar cases. To find out central hypothyroidism, low cholesterol
levels were good markers.